Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Bolt Biotherapeutics (BOLT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: BOLT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $22.25
1 Year Target Price $22.25
| 1 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -56.28% | Avg. Invested days 18 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.35M USD | Price to earnings Ratio - | 1Y Target Price 22.25 |
Price to earnings Ratio - | 1Y Target Price 22.25 | ||
Volume (30-day avg) 4 | Beta 0.92 | 52 Weeks Range 4.59 - 13.40 | Updated Date 11/6/2025 |
52 Weeks Range 4.59 - 13.40 | Updated Date 11/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -26.42 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -510.53% |
Management Effectiveness
Return on Assets (TTM) -33.45% | Return on Equity (TTM) -81.33% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -1065573 | Price to Sales(TTM) 2.24 |
Enterprise Value -1065573 | Price to Sales(TTM) 2.24 | ||
Enterprise Value to Revenue 0.01 | Enterprise Value to EBITDA 0.93 | Shares Outstanding 1919441 | Shares Floating 1440406 |
Shares Outstanding 1919441 | Shares Floating 1440406 | ||
Percent Insiders 7.11 | Percent Institutions 44.61 |
Upturn AI SWOT
Bolt Biotherapeutics
Company Overview
History and Background
Bolt Biotherapeutics, founded in 2015, is a clinical-stage biotechnology company focused on developing immunotherapies that harness the power of the immune system to eradicate cancer. It went public in 2021. Bolt has focused on its Boltbodyu2122 Immune-Stimulating Antibody (ISA) platform.
Core Business Areas
- Immuno-oncology: Develops novel immunotherapies for the treatment of cancer, leveraging its Boltbodyu2122 ISA platform.
- Research and Development: Conducts research to identify and develop new therapeutic candidates.
Leadership and Structure
Dr. Mark Frohberger is the President and CEO. The company has a scientific advisory board and a board of directors overseeing its operations.
Top Products and Market Share
Key Offerings
- BDT001: A Boltbodyu2122 ISA targeting solid tumors expressing HER2. Currently in Phase 1/2 clinical trials. Market share data is not publicly available; competition includes other HER2-targeted therapies from companies such as Roche (ROG) and Genentech (a Roche subsidiary).
- BDT001 Revenue:
- BDC-3045: A Boltbodyu2122 ISA targeting Dectin-2. In preclinical development. Market share data is not publicly available; competition includes companies targeting innate immune pathways like Innate Pharma (IPHA).
- BDC-3045 Revenue:
Market Dynamics
Industry Overview
The immuno-oncology market is experiencing significant growth, driven by the success of checkpoint inhibitors and the increasing understanding of the role of the immune system in cancer. It is a competitive landscape with numerous companies developing novel immunotherapies.
Positioning
Bolt Biotherapeutics is positioned as an innovative company with its Boltbodyu2122 ISA platform. Its competitive advantage lies in its ability to engage the innate immune system to target tumors directly.
Total Addressable Market (TAM)
The global immuno-oncology market is estimated to reach hundreds of billions of dollars. Bolt Biotherapeutics aims to capture a portion of this market with its novel immunotherapies.
Upturn SWOT Analysis
Strengths
- Novel Boltbodyu2122 ISA platform
- Targeting the innate immune system
- Experienced leadership team
- Proprietary technology
Weaknesses
- Limited clinical data
- Dependence on a single platform
- High cash burn rate
- Early stage development
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of Boltbodyu2122 ISA platform to new targets
- Positive clinical trial results
- Growing immuno-oncology market
Threats
- Competition from established immuno-oncology therapies
- Clinical trial failures
- Regulatory hurdles
- Economic downturn
Competitors and Market Share
Key Competitors
- ROG
- MRTX
- NK
- AGEN
Competitive Landscape
Bolt Biotherapeutics's Boltbodyu2122 ISA platform offers a novel approach to immuno-oncology, but it competes with well-established therapies and companies with greater resources. Its success depends on demonstrating clinical efficacy and safety.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is measured by progress in research and development, clinical trial advancement, and establishment of partnerships.
Future Projections: Future projections are based on the success of clinical trials and the potential for partnerships and licensing agreements. Analyst estimates vary depending on trial outcomes.
Recent Initiatives: Recent initiatives include advancing BDT001 and BDC-3045 into later-stage clinical trials, exploring new targets for the Boltbodyu2122 ISA platform, and securing additional funding.
Summary
Bolt Biotherapeutics is a high-risk, high-reward biotech company with a promising immuno-oncology platform. Positive clinical trial data for its lead candidates is essential for future success. It needs to manage its cash burn carefully and explore partnership opportunities. The company is an early stage startup that will need to be carefully scrutinized.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is estimated and may not be precise. Investing in biotechnology companies is inherently risky.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bolt Biotherapeutics
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2021-02-05 | CEO, CFO, President, Secretary & Director Mr. William P. Quinn | ||
Sector Healthcare | Industry Biotechnology | Full time employees 52 | Website https://www.boltbio.com |
Full time employees 52 | Website https://www.boltbio.com | ||
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company dBDC-3042, develops dan agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer; and BDC-4182, an next-generation boltbody technology platform that targets claudin 18.2, which is overexpressed in gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc.; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.